Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case–controlled study
出版年份 2020 全文链接
标题
Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case–controlled study
作者
关键词
-
出版物
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE
Volume 113, Issue 8, Pages 546-550
出版商
Oxford University Press (OUP)
发表日期
2020-06-12
DOI
10.1093/qjmed/hcaa206
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China
- (2020) Zunyou Wu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
- (2020) Chaolin Huang et al. LANCET
- Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study
- (2020) Xiaobo Yang et al. Lancet Respiratory Medicine
- Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy
- (2020) Paola Toniati et al. AUTOIMMUNITY REVIEWS
- Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia
- (2020) Ruggero Capra et al. European Journal of Internal Medicine
- Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area
- (2020) Safiya Richardson et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy
- (2020) Giacomo Grasselli et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis
- (2020) Zhaohai Zheng et al. JOURNAL OF INFECTION
- Tocilizumab treatment in COVID-19: A single center experience
- (2020) Pan Luo et al. JOURNAL OF MEDICAL VIROLOGY
- Why tocilizumab could be an effective treatment for severe COVID-19?
- (2020) Binqing Fu et al. Journal of Translational Medicine
- Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients
- (2020) T. Klopfenstein et al. MEDECINE ET MALADIES INFECTIEUSES
- Effective treatment of severe COVID-19 patients with tocilizumab
- (2020) Xiaoling Xu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE)
- (2020) Marta Colaneri et al. Microorganisms
- Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
- (2020) Bingwen Liu et al. JOURNAL OF AUTOIMMUNITY
- Prediction of infection risk in rheumatoid arthritis patients treated with biologics
- (2019) Meghna Jani et al. CURRENT OPINION IN RHEUMATOLOGY
- Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology
- (2017) Rudragouda Channappanavar et al. Seminars in Immunopathology
- Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis
- (2012) Fabrizio De Benedetti et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started